瑞联新材: 关于终止部分募集资金投资项目的公告

Core Viewpoint - The company has decided to terminate the raw material drug project due to uncertainties in the project's second phase and aims to find more profitable projects for the remaining raised funds [2][8][10]. Fundraising Overview - The company raised a total of RMB 1,995.79 million by issuing 17.55 million shares at RMB 113.72 per share [2][3]. - As of June 30, 2025, the cumulative investment in the raw material drug project was RMB 178.70 million, with pending payments of RMB 6.11 million and remaining funds of RMB 215.69 million [2][6]. Investment Projects - The company has several fundraising investment projects, including: - OLED and other functional materials production project with a total investment of RMB 300.00 million [4]. - High-end liquid crystal display materials production project with a total investment of RMB 310.00 million [4]. - Resource harmless treatment project with a total investment of RMB 37.21 million [4]. - Research and testing center project with an investment of RMB 170.00 million [4]. - Working capital supplement of RMB 260.00 million [4]. Termination of Investment Project - The raw material drug project was intended to expand the company's pharmaceutical CDMO business, with a total investment of RMB 423.00 million, using RMB 369.00 million of excess raised funds [6][8]. - The first phase of the project has been completed, but the second phase has not started due to uncertainties in product planning and regulatory approval processes [7][8]. Impact of Termination - The decision to terminate the raw material drug project is based on current industry trends and aims to optimize the use of resources and funds, ensuring high-quality project implementation [8][10]. - The termination is not expected to adversely affect the company's normal operations and aligns with its long-term development strategy [8][10]. Review Procedures - The board and supervisory committee approved the termination of the investment project, which will be submitted for shareholder approval [10][11]. - The supervisory committee and the sponsor institution have expressed their agreement with the decision, confirming that it complies with relevant regulations and does not harm shareholder interests [10][11].